Related Experiment Video
Updated: May 26, 2026

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
Published on: July 19, 2024
[Omega-3 fatty acids as an option in the treatment of NAFLD]
1Mitglied der ISSFAL (International Society for the Study of Fatty Acids and Lipids), der DAEM (Deutsche Akademie for Ernihrungsmedizin) und des Wissenschaftlichen Beirats im Arbeitskreis Omega-3 e.V., Berlin.
Background:
Human tissues or organs vary in the content of long-chain omega-3 fatty acids, in case of diseases the content may even change. These findings cannot be extrapolated from blood lipids.
Methods:
Overview
Results:
By means of liver biopsies it has been shown that eicosapentaenoic acid (EPA) significantly decreases with raising triglyceride accumulation in hepatocytes. This is associated with increased histological signs of inflammation in liver parenchyma. In a study the intake of omega-3 fatty acids (1 g/d) resulted in a rising percentage of EPA in liver triglycerides associated with a reduction of liver fat and inflammation markers.
Conclusion:
From the results a hitherto widely ignored indication for NAFLD with or without metabolic syndrome can be derived.
More Related Videos
09:04DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
Published on: February 27, 2014
08:20Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model
Published on: December 2, 2022
Related Concept Videos
Atherosclerosis III: Management
Structure of Lipids
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Nephrotic Syndrome III : Nursing Management
Lipids: Dietary Sources and Requirements
Lipid Digestion